CEO Nicolas Poirier on OSE Immunotherapeutics Latest IL-7 Data
Citeline Podcasts - Een podcast door Citeline
Categorieën:
OSE Immunotherapeutics' CEO Nicolas Poirier talks about the company's IL-7 receptor agonist, lusvertikimab, recent data presented at The European Crohn's and Colitis Organization congress, commercialization and development strategy and the future of IBD therapy.
